Ozdemir, O; Zengel, B; Yildiz, Y; Uluc, BO; Cabuk, D; Ozden, E; Salim, DK; Paydas, S; Demir, A; Diker, O; Pilanci, KN; Sonmez, OU; Vatansever, S; Dogan, I; Gulmez, A; Cakar, B; Gursoy, P; Yildirim, ME; Ayhan, M; Karadurmus, N; Aykan, MB; Cevik, GT; Sakalar, T; Hacibekiroglu, I; Gulbagci, BB; Dincer, M; Garbioglu, DB; Kemal, Y; Nayir, E; Taskaynatan, H; Yilmaz, M; Avci, O; Sari, M; Coban, E; Atci, MM; Esen, SA; Telli, TA; Karatas, F; Inal, A; Demir, H; Kalkan, NO; Yilmaz, C; Tasli, F; Alacacioglu, A
(2022)
In our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer. This study was conducted ...